Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-744-6792
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.38 billion
Profitability
Miscellaneous
Employees20,700
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Bausch Health Companies (NYSE:BHC) Frequently Asked Questions
What is Bausch Health Companies' stock symbol?
Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."
How were Bausch Health Companies' earnings last quarter?
Bausch Health Companies Inc (NYSE:BHC) issued its quarterly earnings data on Wednesday, February, 20th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The business earned $2.12 billion during the quarter, compared to analyst estimates of $2.08 billion. Bausch Health Companies had a negative net margin of 50.83% and a positive return on equity of 39.91%. The firm's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.98 EPS. View Bausch Health Companies' Earnings History.
When is Bausch Health Companies' next earnings date?
What guidance has Bausch Health Companies issued on next quarter's earnings?
Bausch Health Companies updated its FY 2019 earnings guidance on Wednesday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.3-8.5 billion, compared to the consensus revenue estimate of $8.49 billion.
What price target have analysts set for BHC?
18 brokers have issued 12 month price targets for Bausch Health Companies' stock. Their predictions range from $16.00 to $41.00. On average, they expect Bausch Health Companies' share price to reach $27.2619 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.
What is the consensus analysts' recommendation for Bausch Health Companies?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 4 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bausch Health Companies.
What are Wall Street analysts saying about Bausch Health Companies stock?
Here are some recent quotes from research analysts about Bausch Health Companies stock:
- 1. According to Zacks Investment Research, "Bausch’s performance in the fourth quarter was encouraging. After a tumultuous period, Bausch started a rebuilding process. The company also changed its name. Even though it is still early to comment on the rebuilding process, Bausch’s efforts to sell non-core assets and pay down huge levels of debt are commendable. The company recorded 1% organic growth in 2018 and reduced debt by more than $1 billion. Bausch repaid $400 million of debt in the fourth quarter of 2018. Bausch has narrowed its focus on seven recently launched or expected to be launched products, pending completion of testing and receipt of FDA approval. Bausch's Salix business continues to drive growth and contribute to the top line. In particular, increased sales of Xifaxan is boosting the segment. However, the dermatology market continues to be challenging. Shares have performed better than the industry in the past six months." (3/5/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which takes the GAAP net loss of ~$2.08B and adds back $400M in asset impairment-related charges, $189M in tax-related expenses, and $2.94B in amortization-related charges. This yields total adjusted (non-GAAP) income of roughly $1.5B, which we divide by approximately 360M shares outstanding to derive our 12-month cash EPS of $5.51 per share." (2/28/2019)
- 3. Cantor Fitzgerald analysts commented, ". Post a beat and raise quarter, we reiterating our OW rating and 12-month price target of C$32 for BHC shares. We think a greater appreciation for BHC’s solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+." (11/6/2018)
Has Bausch Health Companies been receiving favorable news coverage?
Headlines about BHC stock have trended neutral on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Bausch Health Companies earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Bausch Health Companies' key competitors?
Some companies that are related to Bausch Health Companies include Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Bausch Health Companies own?
Who are Bausch Health Companies' key executives?
Bausch Health Companies' management team includes the folowing people:
- Mr. Joseph C. Papa, CEO & Chairman (Age 64)
- Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
- Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
- Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
- Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)
Who are Bausch Health Companies' major shareholders?
Bausch Health Companies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (2.42%), Dimensional Fund Advisors LP (1.16%), Orbimed Advisors LLC (1.03%), Norges Bank (0.91%), Bank of Montreal Can (0.83%) and Thrivent Financial for Lutherans (0.74%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De and Thomas Appio. View Institutional Ownership Trends for Bausch Health Companies.
Which institutional investors are selling Bausch Health Companies stock?
BHC stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Bank of Montreal Can, FMR LLC, O Shaughnessy Asset Management LLC, Amundi Pioneer Asset Management Inc., Montrusco Bolton Investments Inc., Assenagon Asset Management S.A. and Daiwa Securities Group Inc.. View Insider Buying and Selling for Bausch Health Companies.
Which institutional investors are buying Bausch Health Companies stock?
BHC stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Orbimed Advisors LLC, Ardevora Asset Management LLP, Two Sigma Advisers LP, Two Sigma Investments LP, Thrivent Financial for Lutherans, Canada Pension Plan Investment Board and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De and Thomas Appio. View Insider Buying and Selling for Bausch Health Companies.
How do I buy shares of Bausch Health Companies?
Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bausch Health Companies' stock price today?
One share of BHC stock can currently be purchased for approximately $24.69.
How big of a company is Bausch Health Companies?
Bausch Health Companies has a market capitalization of $8.64 billion and generates $8.38 billion in revenue each year. The company earns $-4,148,000,000.00 in net income (profit) each year or $4.02 on an earnings per share basis. Bausch Health Companies employs 20,700 workers across the globe.
What is Bausch Health Companies' official website?
How can I contact Bausch Health Companies?
Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]
MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
